Generated by AI
Allarity Therapeutics Inc. is a clinical-stage precision medicine biopharmaceutical company focused on developing personalized cancer treatments. Its current work centers on stenoparib, an investigational therapy being studied for advanced recurrent ovarian cancer, alongside its proprietary Drug Response Predictor technology, which is designed to help identify patients most likely to benefit from specific oncology drugs. The company also supports a limited portfolio of additional cancer-focused programs and companion diagnostics intended to improve treatment selection and clinical decision-making. Allarity Therapeutics operates primarily in the oncology and drug development segments, with activities in the United States and Denmark. As a specialist in biomarker-guided cancer care, the company occupies a niche role in the broader pharmaceutical market by combining therapeutic development with diagnostic tools to support more targeted treatment approaches.
Website123 E. Tarpon Ave.
Tarpon Springs, FL, 34689
United States
The latest articles about ALLR.
Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors Strengthens intellectual property supporting the dosing strategy used in the Company's ongoing Phase 2 program TARPON SPRINGS, Fla., November 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the
- Ended third quarter with $24.1 million in cash and restricted cash- Expects positive fourth quarter earnings between $0.01 and $0.04 per share TARPON SPRINGS, Fla., November 13, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today reported financial results for the third quarter ended September 30, 2026, and provide
Summary of Nov 17's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the United States - Strategy expands commercial use of existing laboratory capabilities- Stenoparib remains the Company’s top development priority TARPON SPRINGS, Fla., October 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage
Summary of Sep 22's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Investors talking about ALLR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.